Compugen Ltd
NASDAQ:CGEN
Compugen Ltd
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Revenue Drop: Compugen reported Q3 2025 revenue of approximately $1.9 million, a sharp decline from $17.1 million in the same period last year.
Cash Position: As of September 30, 2025, the company had around $86 million in cash and equivalents, with a cash runway expected into Q3 2027.
Pipeline Progress: The company highlighted strong momentum in its Fc-reduced anti-TIGIT and bispecific antibody programs, with key clinical readouts anticipated from 2026 onwards.
Clinical Trial Update: The interim analysis for the COM701 myovarian trial has been pushed to Q1 2027, mainly due to additional academic site openings and enrollment pacing.
Strategic Partnerships: Compugen emphasized the commercial potential of its partnerships with AstraZeneca and Gilead, with possible milestones exceeding $1 billion plus royalties.
Net Loss: Q3 2025 net loss was $6.98 million, a significant shift from a net profit of $1.28 million in Q3 2024.
Trial Differentiation: Management stressed the advantages of their Fc-reduced antibody formats over Fc-active competitors, citing safety and efficacy data as key differentiators.
